Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 02 2019
15 02 2019
Historique:
received:
11
09
2018
revised:
20
09
2018
accepted:
01
10
2018
pubmed:
7
10
2018
medline:
20
11
2019
entrez:
7
10
2018
Statut:
ppublish
Résumé
Despite a number of preclinical studies demonstrating that the activity of anti-CTLA-4 antibodies in murine models of cancer relies on effector T-cell activation and regulatory T cell depletion, the activity of the clinical antibodies remains controversial. To decipher such mechanisms is critical to the development of novel and more potent immunotherapies.See related article by Sharma et al., p. 1233.
Identifiants
pubmed: 30291135
pii: 1078-0432.CCR-18-2509
doi: 10.1158/1078-0432.CCR-18-2509
doi:
Substances chimiques
CTLA-4 Antigen
0
FOXP3 protein, human
0
Forkhead Transcription Factors
0
Foxp3 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
1130-1132Subventions
Organisme : Cancer Research UK
ID : C36463/A22246
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C36463/A20764
Pays : United Kingdom
Organisme : Department of Health
ID : 167097
Pays : United Kingdom
Commentaires et corrections
Type : CommentOn
Informations de copyright
©2018 American Association for Cancer Research.